国际妇产科学杂志2026，Vol.53Issue(3)：285-291,7.DOI:10.12280/gjfckx.20251450
p53突变型子宫内膜癌免疫微环境特征及免疫治疗进展
Research Advances in the Immune Microenvironment and Immunotherapy for p53-Abnormal Endometrial Carcinoma
相骁莹 1孙雅歌 1张云凤 1贾涵 1王悦1
作者信息
- 1. 450003 郑州大学人民医院,河南省人民医院妇产科
- 折叠
摘要
Abstract
The p53-abnormal(p53abn)subtype is the molecular subtype with the worst prognosis in endometrial cancer.Its immune microenvironment exhibits significant suppressive features,including functional exhausion of CD8+T cells,enrichment of regulatory T cells,and polarization toward M2-type macrophages.Although this subtype generally demonstrates low tumor mutational burden and high chromosomal instability,resulting in weak immunogenicity,a subset of cases show high expression of programmed death-ligand 1(PD-L1)and are enriched in T cells,displaying heterogeneity as'hot tumors'.In terms of treatment,immune checkpoint inhibitors as monotherapy have limited efficacy.However,multiple phase Ⅲ clinical trials have confirmed that combining immunotherapy with chemotherapy,anti-angiogenic agents,or poly(ADP-ribose)polymerase(PARP)inhibitors can significantly improve patient outcomes,particularly in advanced or recurrent cases.This review summarizes the research progress on the characteristics of the immune microenvironment and immunotherapy strategies for p53abn endometrial cancer,providing theoretical foundations and practical reference for clinical precision subtyping,immunotherapy decision-making,and optimization of combination regimens.关键词
基因,p53/子宫内膜肿瘤/癌/肿瘤微环境/免疫检查点抑制剂/抗肿瘤联合化疗方案Key words
Genes,p53/Endometrial neoplasms/Carcinoma/Tumor microenvironment/Immune checkpoint inhibitors/Antineoplastic combined chemotherapy protocols引用本文复制引用
相骁莹,孙雅歌,张云凤,贾涵,王悦..p53突变型子宫内膜癌免疫微环境特征及免疫治疗进展[J].国际妇产科学杂志,2026,53(3):285-291,7.
